Effects of (±)3,4-methylenedioxymethamphetamine, (±)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques

Neuroscience

Volumn 142, Issue 2, 2006, Pages 515-525

  Crean, R D ^a   Davis, S A ^a   Von Huben, S N ^a   Lay, C C ^a   Katner, S N ^a   Taffe, M A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

amphetamine; circadian; neurotoxicity; serotonin; thermoregulation

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; METHAMPHETAMINE; PSYCHEDELIC AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CAGE; CIRCADIAN RHYTHM; CONTROLLED STUDY; HYPERTHERMIA; LOCOMOTION; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; STATISTICAL SIGNIFICANCE; TELEMETRY; THERMOREGULATION; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; MACACA; MOTOR ACTIVITY; TIME;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MACACA MULATTA; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; TIME FACTORS;

EID: 33748929632     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2006.06.033     Document Type: Article

References (74)

1. Ali S.F., Newport G.D., Scallet A.C., Binienda Z., Ferguson S.A., Bailey J.R., Paule M.G., and Slikker Jr. W. Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol 15 (1993) 91-96
2. Almirall H., Bautista V., Sanchez-Bahillo A., and Trinidad-Herrero M. Ultradian and circadian body temperature and activity rhythms in chronic MPTP treated monkeys. Neurophysiol Clin 31 (2001) 161-170
3. Baggott M., Heifets B., Jones R.T., Mendelson J., Sferios E., and Zehnder J. Chemical analysis of ecstasy pills. JAMA 284 (2000) 2190
4. Ball J., Garfield T., Morin C., and Steele D. Emergency department trends from the Drug Abuse Warning Network, final estimates 1995-2002. DAWN series D-24, DHHS publication no. (SMA) 03-3780 (2003), Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD
5. Ball J., Morin C., Cover E., Green J., Sonnefeld J., Steele D., Williams T., and Mallonee E. Drug Abuse Warning Network, 2003: interim national estimates of drug-related emergency department visits. DAWN series D-26, DHHS publication no. (SMA) 04-3972 (2004), Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Rockville, MD
6. Battaglia G., and De Souza E.B. Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr 94 (1989) 240-258
7. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker Jr. W., and Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 268 (1994) 1571-1580
8. Bowyer J.F., Tank A.W., Newport G.D., Slikker Jr. W., Ali S.F., and Holson R.R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260 (1992) 817-824
9. Bowyer J.F., Young J.F., Slikker W., Itzak Y., Mayorga A.J., Newport G.D., Ali S.F., Frederick D.L., and Paule M.G. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24 (2003) 379-390
10. Broening H.W., Morford L.L., and Vorhees C.V. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 56 (2005) 84-93
11. Brown P.L., and Kiyatkin E.A. Brain hyperthermia induced by MDMA (ecstasy): modulation by environmental conditions. Eur J Neurosci 20 (2004) 51-58
12. Brown P.L., Wise R.A., and Kiyatkin E.A. Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci 23 (2003) 3924-3929
13. Carvalho M., Carvalho F., Remiao F., de Lourdes Pereira M., Pires-das-Neves R., and de Lourdes Bastos M. Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch Toxicol 76 (2002) 166-172
14. Clark J.D., Baldwin R.L., Bayne K.A., Brown M.J., Gebhart G.F., Gonder J.C., Gwathmey J.K., Keeling M.E., Kohn D.F., Robb J.W., Smith O.A., Steggarda J.-A.D., Vandenbergh J.G., White W.J., Williams-Blangero S., and VandeBerg J.L. Guide for the care and use of laboratory animals (1996), Institute of Laboratory Animal Resources, National Research Council, Washington, DC
15. Clingerman K.J., and Summers L. Development of a body condition scoring system for nonhuman primates using Macaca mulatta as a model. Lab Anim (NY) 34 (2005) 31-36
16. Dafters R.I. Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology (Berl) 114 (1994) 505-508
17. Dams R., De Letter E.A., Mortier K.A., Cordonnier J.A., Lambert W.E., Piette M.H., Van Calenbergh S., and De Leenheer A.P. Fatality due to combined use of the designer drugs MDMA and PMA: a distribution study. J Anal Toxicol 27 (2003) 318-322
18. Davis W.M., Hatoum H.T., and Waters I.W. Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (ecstasy) abuse. Alcohol Drug Res 7 (1987) 123-134
19. de la Torre R., Farre M., Roset P.N., Pizarro N., Abanades S., Segura M., Segura J., and Cami J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26 (2004) 137-144
20. Fantegrossi W.E., Godlewski T., Karabenick R.L., Stephens J.M., Ullrich T., Rice K.C., and Woods J.H. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) 166 (2003) 202-211
21. Fantegrossi W.E., Kiessel C.L., De la Garza II R., and Woods J.H. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology (Berl) 181 (2005) 529-536
22. Fiege M., Wappler F., Weisshorn R., Gerbershagen M.U., Menge M., and Schulte Am Esch J. Induction of malignant hyperthermia in susceptible swine by 3,4-methylenedioxymethamphetamine ("ecstasy"). Anesthesiology 99 (2003) 1132-1136
23. Frederick D.L., Ali S.F., Gillam M.P., Gossett J., Slikker W., and Paule M.G. Acute effects of dexfenfluramine (d-FEN) and methylenedioxymethamphetamine (MDMA) before and after short-course, high-dose treatment. Ann N Y Acad Sci 844 (1998) 183-190
24. Freedman R.R., Johanson C.E., and Tancer M.E. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 183 (2005) 248-256
25. Freezer A., Salem A., and Irvine R.J. Effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide. Brain Res 1041 (2005) 48-55
26. Gillman P.K. Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. Med J Aust 167 109 (1997) 111
27. Gouzoulis-Mayfrank E., and Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?. Addiction 101 (2006) 348-361
28. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55 (2003) 463-508
29. Greene S.L., Dargan P.I., O'Connor N., Jones A.L., and Kerins M. Multiple toxicity from 3,4-methylenedioxymethamphetamine ("ecstasy"). Am J Emerg Med 21 (2003) 121-124
30. Grob C.S., Poland R.E., Chang L., and Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73 (1996) 103-107
31. Han D.D., and Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol (2006). http://dx.doi.org/10.1186/1471-2210-6-6 3 Mar [Epub ahead of print] http://dx.doi.org/10.1186/1471-2210-6-6
32. Hardman H.F., Haavik C.O., and Seevers M.H. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 25 (1973) 299-309
33. Henry J.A., Jeffreys K.J., and Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340 (1992) 384-387
34. Herin D.V., Liu S., Ullrich T., Rice K.C., and Cunningham K.A. Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine. Psychopharmacology (Berl) 178 (2005) 505-513
35. Horn T.F., Huitron-Resendiz S., Weed M.R., Henriksen S.J., and Fox H.S. Early physiological abnormalities after simian immunodeficiency virus infection. Proc Natl Acad Sci U S A 95 (1998) 15072-15077
36. Kamijo Y., Soma K., Nishida M., Namera A., and Ohwada T. Acute liver failure following intravenous methamphetamine. Vet Hum Toxicol 44 (2002) 216-217
37. Katner S.N., Flynn C.T., Von Huben S.N., Kirsten A.J., Davis S.A., Lay C.C., Cole M., Roberts A.J., Fox H.S., and Taffe M.A. Controlled and behaviorally relevant levels of oral ethanol intake in rhesus macaques using a flavorant-fade procedure. Alcohol Clin Exp Res 28 (2004) 873-883
38. Kojima T., Une I., Yashiki M., Noda J., Sakai K., and Yamamoto K. A fatal methamphetamine poisoning associated with hyperpyrexia. Forensic Sci Int 24 (1984) 87-93
39. Kraemer T., and Maurer H.H. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 24 (2002) 277-289
40. Levy K.B., O'Grady K.E., Wish E.D., and Arria A.M. An in-depth qualitative examination of the ecstasy experience: results of a focus group with ecstasy-using college students. Subst Use Misuse 40 (2005) 1427-1441
41. Liechti M.E., Saur M.R., Gamma A., Hell D., and Vollenweider F.X. Psychological and physiological effects of MDMA ("ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23 (2000) 396-404
42. Madden L.J., Flynn C.T., Zandonatti M.A., May M., Parsons L.H., Katner S.N., Henriksen S.J., and Fox H.S. Modeling human methamphetamine exposure in nonhuman primates: chronic dosing in the rhesus macaque leads to behavioral and physiological abnormalities. Neuropsychopharmacology 30 (2005) 350-359
43. Malberg J.E., and Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 18 (1998) 5086-5094
44. Mallick A., and Bodenham A.R. MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accid Emerg Med 14 (1997) 336-338
45. Mas M., Farre M., de la Torre R., Roset P.N., Ortuno J., Segura J., and Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290 (1999) 136-145
46. Mechan A., Yuan J., Hatzidimitriou G., Irvine R.J., McCann U.D., and Ricaurte G.A. Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31 (2006) 339-350
47. Mechan A.O., Esteban B., O'Shea E., Elliott J.M., Colado M.I., and Green A.R. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") to rats. Br J Pharmacol 135 (2002) 170-180
48. Melega W.P., Lacan G., Harvey D.C., Huang S.C., and Phelps M.E. Dizocilpine and reduced body temperature do not prevent methamphetamine-induced neurotoxicity in the vervet monkey: [11C]WIN 35,428-positron emission tomography studies. Neurosci Lett 258 (1998) 17-20
49. Miller D.B., and O'Callaghan J.P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270 (1994) 752-760
50. Morgan M.J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 152 (2000) 230-248
51. NRC/NAS. Nutrient requirements of nonhuman primates. second revised edition. (2003), National Research Council of the National Academy of Sciences, Washington, DC
52. Parrott A.C. Human research on MDMA (3,4-methylene-dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42 (2000) 17-24
53. Parrott A.C. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16 (2001) 557-577
54. Patel M.M., Belson M.G., Longwater A.B., Olson K.R., and Miller M.A. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med 29 (2005) 451-454
55. Pedersen N.P., and Blessing W.W. Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci 21 (2001) 8648-8654
56. Ricaurte G.A., DeLanney L.E., Irwin I., and Langston J.W. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 446 (1988) 165-168
57. Ricaurte G.A., Yuan J., Hatzidimitriou G., Cord B.J., and McCann U.D. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science 297 (2002) 2260-2263
58. Ricaurte G.A., Yuan J., Hatzidimitriou G., Cord B.J., and McCann U.D. Retraction. Science 301 (2003) 1479
59. Rosa-Neto P., Olsen A.K., Gjedde A., Watanabe H., and Cumming P. MDMA-evoked changes in cerebral blood flow in living porcine brain: correlation with hyperthermia. Synapse 53 (2004) 214-221
60. Saadat K.S., Elliott J.M., Colado M.I., and Green A.R. Hyperthermic and neurotoxic effect of 3,4-methylenedioxymethamphetamine (MDMA) in guinea pigs. Psychopharmacology (Berl) 173 (2004) 452-453
61. Saadat K.S., O'Shea E., Colado M.I., Elliott J.M., and Green A.R. The role of 5-HT in the impairment of thermoregulation observed in rats administered MDMA ("ecstasy") when housed at high ambient temperature. Psychopharmacology (Berl) 179 (2005) 884-890
62. Sprague J.E., Moze P., Caden D., Rusyniak D.E., Holmes C., Goldstein D.S., and Mills E.M. Carvedilol reverses hyperthermia and attenuates rhabdomyolysis induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) in an animal model. Crit Care Med 33 (2005) 1311-1316
63. Taffe M.A. Effects of parametric feeding manipulations on behavioral performance in macaques. Physiol Behav 81 (2004) 59-70
64. Taffe M.A. Erratum: Effects of parametric feeding manipulations on behavioral performance in macaques. Physiol Behav 82 (2004) 589
65. Taffe M.A., Davis S.A., Yuan J., Schroeder R., Hatzidimitriou G., Parsons L.H., Ricaurte G.A., and Gold L.H. Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge. Neuropsychopharmacology 27 (2002) 993-1005
66. Taffe M.A., Lay C.C., Von Huben S.N., Davis S.A., Crean R.D., and Katner S.N. Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys. Drug Alcohol Depend 82 (2006) 276-281
67. Taffe M.A., Weed M.R., Davis S., Huitron-Resendiz S., Schroeder R., Parsons L.H., Henriksen S.J., and Gold L.H. Functional consequences of repeated (+/-)3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys. Neuropsychopharmacology 24 (2001) 230-239
68. Takasu N., Nigi H., and Tokura H. Effects of diurnal bright/dim light intensity on circadian core temperature and activity rhythms in the Japanese macaque. Jpn J Physiol 52 (2002) 573-578
69. Tanner-Smith E.E. Pharmacological content of tablets sold as "ecstasy": Results from an online testing service. Drug Alcohol Depend 83 (2006) 247-254
70. Verrico C.D., Miller G.M., and Madras B.K. MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology (Berl) (2005). http://dx.doi.org/10.1007/s00213-005-0174-5 12 Oct [Epub ahead of print] http://dx.doi.org/10.1007/s00213-005-0174-5.
71. Von Huben S.N., Lay C.C., Crean R.D., Davis S.A., Katner S.N., and Taffe M.A. Impact of ambient temperature on hyperthermia induced by (±)3,4-methylenedioxymethamphetamine in rhesus macaques. Neuropsychoparmacology (2006). http://dx.doi.org/10.1038/sj.npp.1301078 12 Apr [Epub ahead of print] http://dx.doi.org/10.1038/sj.npp.1301078.
72. Wallace M.E., and Squires R. Fatal massive amphetamine ingestion associated with hyperpyrexia. J Am Board Fam Pract 13 (2000) 302-304
73. Winsauer P.J., McCann U.D., Yuan J., Delatte M.S., Stevenson M.W., Ricaurte G.A., and Moerschbaecher J.M. Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration. Psychopharmacology (Berl) 159 (2002) 388-396
74. Yuan J., Hatzidimitriou G., Suthar P., Mueller M., McCann U., and Ricaurte G. Relationship between temperature, dopaminergic neurotoxicity, and plasma drug concentrations in methamphetamine-treated squirrel monkeys. J Pharmacol Exp Ther 316 (2006) 1210-1218